SPAC4F10.17 Antibody

What is SPA17 and why is it significant in cancer research?

SPA17 (Sperm autoantigenic protein 17) is a cell surface protein initially characterized by its involvement in the binding of sperm to the zona pellucida of the oocyte. The N-terminus has sequence similarity to human cAMP-dependent protein kinase A (PKA) type II alpha regulatory subunit (RIIa), while the C-terminus has an IQ calmodulin-binding motif. The central portion contains carbohydrate binding motifs that likely function in cell-cell adhesion .

SPA17 has gained significant attention in cancer research as a cancer testis antigen that is overexpressed in various gynecologic malignancies, particularly ovarian cancer. Emerging evidence indicates its involvement in tumorigenesis and malignant cell migration . These characteristics make it a potential target for cancer immunotherapy and a biomarker for defining tumor subsets and predicting drug responses.

What are the common applications of anti-SPA17 antibodies in research?

Anti-SPA17 antibodies are primarily used in research for:

• Western blotting (WB) to detect SPA17 protein expression in cell lysates and tissue samples

• Immunoprecipitation (IP) to isolate and concentrate SPA17 protein from complex mixtures

• Immunofluorescence (IF) to visualize SPA17 localization within cells and tissues

• Enzyme-linked immunosorbent assays (ELISA) for quantitative detection

• Evaluating SPA17 expression in cancer tissues versus normal tissues

• Investigating the role of SPA17 in cell adhesion, migration, and metastasis mechanisms

• Studying potential therapeutic applications through antibody-dependent cytotoxicity mechanisms

How should SPA17 antibodies be stored and handled in the laboratory?

For optimal performance and longevity, SPA17 antibodies should be stored at -20°C as received. Most preparations remain stable for at least 12 months from the date of receipt when properly stored . For HRP-conjugated antibodies, storage buffer typically consists of PBS (pH 7.3) containing 1% BSA and 50% glycerol . For lyophilized antibodies, reconstitution with PBS (pH 7.3) is recommended, with an additional desalting process for optimal performance .

When handling these antibodies, avoid repeated freeze-thaw cycles as this can significantly reduce antibody activity. Always centrifuge the antibody vial before opening to ensure recovery of all the liquid. For working dilutions, WB applications typically require a 1:2000 dilution for HRP-conjugated antibodies .

How can SPA17 antibodies be utilized in targeting ovarian cancer?

SPA17 antibodies have demonstrated significant potential in targeting ovarian cancer through immune-mediated cytotoxicity mechanisms. Research has shown that while the direct cytotoxicity of anti-SP17 monoclonal antibodies against ovarian cancer cells is relatively weak, their efficacy is substantially enhanced through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) .

Methodologically, researchers can evaluate these mechanisms by:

• Selecting SP17-positive ovarian cancer cell lines as targets and SP17-negative lines as controls

• Using healthy human peripheral blood mononuclear cells (PBMCs) as effectors for ADCC assays

• Employing healthy human serum as a source of complement for CDC assays

• Measuring cytotoxicity through standard methods like LDH release or flow cytometry with viability dyes

• Comparing the cytotoxic effects between SP17-positive and SP17-negative cell populations to confirm specificity

This approach offers insights into developing targeted therapies with potentially reduced side effects compared to conventional chemotherapeutics .

What considerations should be made when selecting an anti-SPA17 antibody clone for research?

When selecting an anti-SPA17 antibody clone for research, several critical factors should be considered:

• Epitope specificity: Different clones target different epitopes of the SPA17 protein. For example, some antibodies target the C-terminus (similar to how IL-17 Antibody G-4 targets amino acids 111-140 at the C-terminus of IL-17) . Understanding the epitope location is crucial for applications where protein conformation matters.

• Species reactivity: Verify that the antibody reacts with the species you're studying. For instance, clone OTI6F10 is reactive against human SPA17 .

• Validated applications: Confirm that the antibody has been validated for your specific application (WB, IP, IF, IHC, ELISA, etc.).

• Conjugation requirements: Determine whether you need a conjugated (e.g., HRP-conjugated) or unconjugated antibody based on your detection method.

• Isotype and host species: Consider the antibody isotype (e.g., IgG1) and host species (e.g., mouse) to ensure compatibility with secondary antibodies and to avoid cross-reactivity in multiplex staining.

• Functional activity: For therapeutic applications, evaluate whether the antibody has demonstrated ADCC or CDC activity in previous studies.

A thorough evaluation of these factors will help ensure the selection of an appropriate antibody clone that will yield reliable and reproducible results in your specific research context.

What are the optimal methodologies for evaluating SPA17 expression in clinical samples?

Evaluating SPA17 expression in clinical samples requires a methodical approach to ensure accurate and reproducible results:

• Sample preparation: For FFPE (formalin-fixed paraffin-embedded) samples, optimal antigen retrieval is crucial, typically using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0). For frozen sections, fixation with acetone or 4% paraformaldehyde is recommended.

• Antibody selection: Choose a well-validated anti-SPA17 antibody with proven specificity. Monoclonal antibodies like clone OTI6F10 offer high specificity and reproducibility .

• Detection methods:

  • Immunohistochemistry (IHC): Use appropriate dilutions (typically starting at 1:100-1:200) with optimized incubation times and temperatures

  • Immunofluorescence: Consider dual staining with cellular markers to determine subcellular localization

  • Western blotting: A recommended dilution of 1:2000 for HRP-conjugated antibodies provides a good starting point

• Controls: Always include:

  • Positive controls (tissues known to express SPA17, such as testis)

  • Negative controls (tissues known not to express SPA17)

  • Isotype controls to detect non-specific binding

  • Antibody controls (omitting primary antibody)

• Scoring systems: Develop or use established scoring systems that consider:

  • Percentage of positive cells

  • Staining intensity (weak, moderate, strong)

  • Subcellular localization (membrane, cytoplasmic, nuclear)

• Validation: Confirm expression using orthogonal methods (e.g., validate IHC findings with RT-PCR or western blotting when possible)

Following these methodological guidelines will help ensure robust and clinically relevant data regarding SPA17 expression patterns in patient samples.

How should experiments be designed to evaluate the specificity of anti-SPA17 antibodies?

Designing experiments to evaluate anti-SPA17 antibody specificity requires a systematic approach:

• Positive and negative cell lines: Use cell lines with confirmed SPA17 expression (such as certain ovarian cancer cell lines) as positive controls and cell lines without SPA17 expression as negative controls .

• Knockout/knockdown validation:

  • Generate SPA17 knockout cell lines using CRISPR-Cas9 technology

  • Alternatively, create SPA17 knockdown cells using siRNA or shRNA

  • Compare antibody reactivity between wild-type and knockout/knockdown cells

• Recombinant protein controls:

  • Test antibody binding to purified recombinant SPA17 protein

  • Use structurally similar proteins as negative controls to assess cross-reactivity

  • The full-length human recombinant SPA17 protein produced in E. coli can serve as a positive control

• Peptide competition assays:

  • Pre-incubate the antibody with excess SPA17 peptide (corresponding to the immunogen)

  • This should block specific binding sites and eliminate true positive signals

  • Non-specific binding will persist despite peptide competition

• Multi-method validation:

  • Confirm specificity using multiple techniques (WB, IP, IF)

  • Western blotting should show a band at the predicted molecular weight (17.2 kDa for SPA17)

  • IP followed by mass spectrometry can confirm the identity of the pulled-down protein

• Epitope mapping:

  • Test antibody binding against truncated variants of SPA17 to confirm epitope specificity

  • This is particularly important when working with antibodies targeting specific domains

These approaches will collectively provide strong evidence regarding antibody specificity and help prevent misinterpretation of experimental results.

What controls should be included in functional studies using anti-SPA17 antibodies?

Functional studies using anti-SPA17 antibodies require comprehensive controls to ensure valid and interpretable results:

• Antibody-specific controls:

  • Isotype control antibody (same isotype, host species, and concentration as the anti-SPA17 antibody)

  • Secondary antibody-only control (omitting primary antibody)

  • Concentration gradient of anti-SPA17 antibody to establish dose-response relationships

• Cell line controls:

  • SPA17-positive cells (expected to respond to the antibody)

  • SPA17-negative cells (should not respond to the antibody)

  • SPA17-knockout or knockdown derivative cell lines

  • Non-malignant cells expressing SPA17 (to assess cancer-specific effects)

• Functional assay controls:

  • For ADCC assays: Include controls without effector cells

  • For CDC assays: Include heat-inactivated serum controls

  • Positive control antibodies with known ADCC/CDC activity

  • Range of effector-to-target (E:T) ratios to establish optimal conditions

• Mechanistic controls:

  • Blocking antibodies against Fc receptors (to confirm Fc-dependent mechanisms)

  • Complement inhibitors (to confirm complement-dependent effects)

  • Signaling pathway inhibitors to dissect downstream mechanisms

• Temporal controls:

  • Time-course experiments to determine optimal incubation periods

  • Antibody pre-incubation studies to assess internalization effects

• Technical replicates and biological replicates:

  • At least three technical replicates per condition

  • Experiments repeated with different batches of antibodies and cells

This comprehensive control strategy will help distinguish specific anti-SPA17 antibody effects from non-specific effects and provide robust evidence for the mechanisms being investigated.

How can researchers address contradictory results when using different anti-SPA17 antibody clones?

Contradictory results when using different anti-SPA17 antibody clones are not uncommon and require a systematic troubleshooting approach:

• Epitope mapping analysis:

  • Different antibody clones recognize different epitopes on the SPA17 protein

  • Map the specific epitopes recognized by each antibody clone

  • Consider whether protein conformation, post-translational modifications, or protein-protein interactions might mask certain epitopes in specific contexts

• Cross-reactivity assessment:

  • Test each antibody against a panel of related proteins

  • Sequence homology analysis between SPA17 and potential cross-reactive proteins

  • Consider that the N-terminus of SPA17 has sequence similarity to PKA RIIα, which might lead to cross-reactivity

• Validation with multiple methods:

  • Compare results across different techniques (WB, IP, IF, IHC)

  • Some antibodies perform well in denatured conditions (WB) but poorly in native conditions (IF), or vice versa

  • Confirm protein identity using mass spectrometry after immunoprecipitation

• Isoform-specific detection:

  • Determine if contradictory results stem from detection of different SPA17 isoforms

  • Design PCR primers to identify which isoforms are expressed in your experimental system

  • Use antibodies that can differentiate between isoforms when possible

• Quantitative comparison:

  • Establish standard curves using recombinant SPA17 protein

  • Compare antibody sensitivity and dynamic range

  • Determine if contradictions are qualitative or quantitative in nature

• Independent validation:

  • Use orthogonal approaches that don't rely on antibodies (e.g., RNA-seq, PCR)

  • Generate tagged SPA17 constructs that can be detected with anti-tag antibodies

When publishing, transparently report all antibody validation efforts and clearly state which clone was used for which experiment, allowing other researchers to better interpret and reproduce your findings.

What methodological approaches can be used to study the therapeutic potential of anti-SPA17 antibodies in cancer?

Investigating the therapeutic potential of anti-SPA17 antibodies requires a multi-faceted approach spanning in vitro, ex vivo, and in vivo methodologies:

• In vitro cytotoxicity assessments:

  • Direct cytotoxicity: Expose SPA17-positive cancer cells to anti-SPA17 antibodies and measure cell viability using MTT/XTT assays, ATP-based assays, or flow cytometry

  • ADCC: Co-culture cancer cells with PBMCs or NK cells in the presence of anti-SPA17 antibodies at various effector-to-target ratios

  • CDC: Expose cancer cells to anti-SPA17 antibodies in the presence of complement-containing serum

  • Compare effects between SPA17-positive and SPA17-negative cell lines to confirm specificity

• Mechanism of action studies:

  • Flow cytometry to assess antibody binding to cancer cells

  • Confocal microscopy to track antibody internalization

  • Western blotting to identify activated signaling pathways

  • Apoptosis assessment using Annexin V/PI staining

  • Cell cycle analysis to determine cell cycle arrest patterns

• Ex vivo patient sample testing:

  • Isolate primary cancer cells from patient samples

  • Screen for SPA17 expression

  • Test antibody efficacy against these primary cells

  • Correlate responses with clinical parameters and SPA17 expression levels

• In vivo model systems:

  • Xenograft models using SPA17-positive cancer cell lines

  • Patient-derived xenograft (PDX) models

  • Humanized mouse models with reconstituted human immune system

  • Metastasis models to assess effects on tumor dissemination

  • Monitor tumor growth, survival, and metastasis formation

• Combination therapy assessment:

  • Test anti-SPA17 antibodies in combination with:

    • Conventional chemotherapeutics

    • Immune checkpoint inhibitors

    • Targeted therapies

    • Radiation therapy

  • Determine synergistic, additive, or antagonistic effects

• Antibody engineering approaches:

  • Compare different antibody formats (IgG, F(ab')₂, scFv)

  • Test antibody-drug conjugates (ADCs) linking anti-SPA17 antibodies to cytotoxic payloads

  • Develop bispecific antibodies targeting SPA17 and immune effector cells

The preliminary finding that anti-Sp17 mAb demonstrates stronger cytotoxicity through ADCC and CDC mechanisms than through direct cytotoxicity suggests these immune-mediated pathways should be emphasized in therapeutic development strategies .

What are common challenges when using SPA17 antibodies in immunohistochemistry and how can they be addressed?

Immunohistochemistry (IHC) with SPA17 antibodies can present several technical challenges that require specific troubleshooting:

• High background staining:

  • Challenge: Non-specific binding creating false positive signals

  • Solution: Increase blocking time (2-3 hours), use a different blocking reagent (5% BSA, 5% normal serum, or commercial blockers), optimize antibody dilution (start with 1:100-1:200 and titrate), and include additional washing steps with 0.1% Tween-20 in PBS

• Weak or absent signal:

  • Challenge: Insufficient antigen detection despite known expression

  • Solution: Optimize antigen retrieval (compare heat-induced epitope retrieval using citrate buffer pH 6.0 vs. EDTA buffer pH 9.0), increase antibody concentration, extend primary antibody incubation (overnight at 4°C), and use signal amplification systems like polymer-HRP or tyramide signal amplification

• Inconsistent staining patterns:

  • Challenge: Variable results between experiments or tissue regions

  • Solution: Standardize fixation times for fresh samples, use automated staining platforms when available, ensure uniform section thickness (4-5 μm), and develop a detailed IHC protocol with precise timing for each step

• False negative results in tumor samples:

  • Challenge: Lack of staining despite SPA17 expression

  • Solution: Include positive control tissues (testis) on the same slide, verify antibody functionality with western blotting of tissue lysates, and consider testing multiple anti-SPA17 antibody clones recognizing different epitopes

• Distinguishing SPA17-specific staining from artifacts:

  • Challenge: Determining true positive signals

  • Solution: Always run parallel staining with isotype control antibodies, include a peptide competition assay (pre-incubating the antibody with SPA17 recombinant protein), and validate positive staining with orthogonal methods like in situ hybridization

• Heterogeneous expression patterns:

  • Challenge: Interpreting variable expression within samples

  • Solution: Develop clear scoring criteria accounting for staining intensity and percentage of positive cells, use digital pathology and image analysis software for quantification, and correlate with clinical or molecular features

A systematic approach to these challenges will improve the reliability and reproducibility of SPA17 immunohistochemistry, providing more accurate assessments of expression patterns in cancer and normal tissues.

How can researchers optimize western blotting protocols for maximum sensitivity when detecting SPA17?

Optimizing western blotting protocols for SPA17 detection requires attention to several key parameters:

• Sample preparation optimization:

  • Use RIPA buffer supplemented with protease inhibitors for extraction

  • Include phosphatase inhibitors to preserve post-translational modifications

  • Sonicate samples briefly (3-5 pulses) to shear DNA and improve protein release

  • Clarify lysates by high-speed centrifugation (15,000 × g for 15 minutes at 4°C)

  • Determine protein concentration using BCA or Bradford assay for equal loading

• Gel electrophoresis considerations:

  • Use 12-15% polyacrylamide gels for optimal resolution of SPA17 (17.2 kDa)

  • Load sufficient protein (20-50 μg per lane for cell lysates)

  • Include molecular weight markers that encompass the 15-20 kDa range

  • Run the gel at lower voltage (80-100V) for better resolution of lower molecular weight proteins

• Transfer optimization:

  • Use PVDF membranes with 0.2 μm pore size (better for smaller proteins)

  • Transfer at lower voltage (25V) overnight at 4°C

  • Add 0.05% SDS to transfer buffer to enhance elution of smaller proteins

  • Verify transfer efficiency using reversible staining (Ponceau S)

• Blocking and antibody incubation:

  • Test different blocking solutions (5% non-fat dry milk vs. 5% BSA in TBST)

  • Optimize antibody dilution (start with manufacturer-recommended 1:2000 for HRP-conjugated antibodies)

  • Incubate primary antibody overnight at 4°C with gentle rocking

  • Extend washing steps (6 × 5 minutes with TBST) to reduce background

• Detection method selection:

  • Use enhanced chemiluminescence (ECL) substrates with extended signal duration

  • Consider fluorescent secondary antibodies for quantitative analysis

  • For very low abundance, use signal enhancement systems like poly-HRP secondaries

  • Optimize exposure times with multiple exposures (short, medium, long)

• Controls and validation:

  • Include positive control (testis tissue lysate or SPA17-overexpressing cells)

  • Run recombinant SPA17 protein as size reference

  • Consider using SPA17 knockout/knockdown samples as negative controls

  • Verify antibody specificity with peptide competition

• Troubleshooting common issues:

  • Multiple bands: Test reducing agent concentration, check for degradation or isoforms

  • No signal: Increase protein loading, reduce washing stringency, check antibody activity

  • High background: Increase blocking time, dilute antibody further, add 0.05% Tween-20 to antibody diluent

Following these optimization steps will help achieve maximum sensitivity and specificity when detecting SPA17 by western blotting, particularly important when working with clinical samples where protein may be limited.